Vitreous -Retina- Macula Consultants of New York
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Vitreous -Retina- Macula Consultants of New York sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Vitreous -Retina- Macula Consultants of New York: 5 sponsored US clinical trials, none currently recruiting.
Vitreous -Retina- Macula Consultants of New York sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy), with 1 trials.
Upper-quartile sponsor footprint
Vitreous -Retina- Macula Consultants of New York sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
NCT01495221
A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)
NCT01115556
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
NCT00403039
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
NCT00403442
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
NCT00403325
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 4 | 1 |
How the Vitreous -Retina- Macula Consultants of New York early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Vitreous -Retina- Macula Consultants of New York: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Vitreous -Retina- Macula Consultants of New York sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Vitreous -Retina- Macula Consultants of New York page
5 registered trials is a research-attention snapshot, not an endorsement of Vitreous -Retina- Macula Consultants of New York or any single study.
- None of Vitreous -Retina- Macula Consultants of New York's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) is the condition Vitreous -Retina- Macula Consultants of New York studies most, compare against other sponsors active in the same condition before evaluating a specific study. See AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vitreous -Retina- Macula Consultants of New York pipeline card: 5 registered trials from official public datasets.Report a data error.